Navigation Links
Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
Date:9/4/2008

- 100 mg cohort demonstrates potent antiviral activity and favorable safety

profile -

CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that it has completed the proof-of-concept study evaluating IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Data from the study demonstrate that the 100 mg/day cohort achieved a mean plasma viral load reduction of 1.87 log10 after seven days of treatment, similar to the potency observed with the other evaluated doses of 800 mg, 400 mg and 200 mg/day in this study. As with the other cohorts, no treatment-related serious adverse events were reported for any of the patients receiving 100 mg/day of IDX899 and no patients discontinued the study.

"We are pleased that HIV-1-infected patients receiving IDX899 in this trial achieved potent viral suppression at all doses tested," said Douglas Mayers, M.D., Idenix's chief medical officer. "With the promising antiviral activity and safety profile seen to date, especially at low doses, we believe that IDX899 could become an important part of combination antiretroviral therapy."

The phase I/II clinical trial was designed to evaluate the safety, tolerability, antiviral activity and pharmacokinetics of IDX899. Four cohorts of 800 mg/day, 400 mg/day, 200 mg/day and 100 mg/day were completed with ten HIV-1-infected treatment-naive patients randomized 8:2 in each cohort to receive oral once-daily IDX899 or matching placebo, respectively, for seven days.

P
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SEATTLE und TÜBINGEN, Deutschland, 5. ... Melinda Gates Stiftung und das deutsche biopharmazeutische ... Stiftung 46 Millionen Euro (52 Millionen US-Dollar) ... im Bereich der medizinisch angewandten Messenger-RNA (mRNA). ... neue Ansätze zur Behandlung von Krankheiten und ...
(Date:3/5/2015)... 5, 2015  As the pharmaceutical industry works ... & Compliance professionals are placing a significant emphasis ... issued today by LRN, the leader in Ethics ... majority of respondents expressed that clarity on company ... of E&C training programs (57%), trumping understanding of ...
(Date:3/5/2015)... , March 5, 2015 Bayer HealthCare announced ... the Conquer Cancer Foundation of the American Society of ... health information technology platform designed to unlock vast quantities ... cancer.  "Bayer is proud to join ... to leverage Big Data to help people whose lives ...
Breaking Medicine Technology:Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3
... Sangart, Inc., a global biopharmaceutical company dedicated to ... perfusion and oxygenation of ischemic (oxygen deprived) tissues ... announced that its investigational biopharmaceutical product, MP4CO, has ... Food and Drug Administration (FDA) for use in ...
... health record (EHR) safety reporting system was announced today ... medical society and professional liability carrier executives in collaboration ... establishes a national system where physicians and other health ... and use of EHRs. Using a ...
Cached Medicine Technology:Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 2Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease 3New National Electronic Health Record Safety System Launched 2New National Electronic Health Record Safety System Launched 3New National Electronic Health Record Safety System Launched 4New National Electronic Health Record Safety System Launched 5New National Electronic Health Record Safety System Launched 6
(Date:3/5/2015)... In honor of National Drug Facts ... drug and alcohol abuse in schools and communities across ... with information on some of the dangers and statistics ... National Institute on Drug Abuse, this annual promotion of ... the illusions that teens and young adults get from ...
(Date:3/5/2015)... 05, 2015 Califia Farms , ... the natural products coffee drinks category[1], today unveils its ... West in Anaheim, Calif. Concentrated Cold Brew (CCB) ... Café, which democratizes the next wave of the coffee-taste ... need to become their own baristas. , Califia ...
(Date:3/5/2015)... York, NY (PRWEB) March 05, 2015 ... orthopedic Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... the New York Metro area. Dr. Glashow has been ... its authoritative guide to the top specialty care doctors ... , The prestigious Castle Connolly program, which carefully screens ...
(Date:3/5/2015)... Nutrition Leaders, a premier purveyor of health, diet, ... Millennium 500 Creatine to its customers. Available from the ... creatine supplement that has been micronized to more quickly ... overall strength gains in users. , Creatine is a ... source in the body and helps fuel muscle contractions ...
(Date:3/5/2015)... 05, 2015 Wimbledon Health Partners ... vascular, echocardiogram and NCV testing, announced the ... Chief Medical Officer. Dr. Artel will be responsible for ... the WimbledonMED program and the continued growth and support ... working with Wimbledon Health Partners as a consulting physician ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... in a Queen,s University-led study do not have an influenza ... tested. In addition, key players were not involved in developing ... not good enough just to have a plan, you have ... will work in an emergency," says Dick Zoutman, Queen,s professor ...
... , AKRON, Ohio , Feb. 10 ... is launching its first bachelor,s degree programs in its 40-year ... Administration with a Business Management concentration Bachelor of Science ... Information Management Bachelor of Science – Technology Management with ...
... or GAD, have abnormalities in the way their brain unconsciously ... School of Medicine study, and the study authors say the ... our understanding of how emotion is regulated in everyday life. ... American Journal of Psychiatry. According to the National ...
... ... celiac disease, one of the most common and under-diagnosed autoimmune diseases, it,s symptoms, and how ... a year, one being day-time Emmy Award winner, Elisabeth Hasselbeck of ABC’s “The View”. ... (PRWEB) February 11, 2010 -- ...
... removal of tumors, study found , WEDNESDAY, Feb. 10 (HealthDay ... levels of spiritual thinking and feeling in patients, a finding ... and the physical makeup of the mind, researchers say. , ... Neuron , are based on research in patients who had ...
... , , PUYALLUP, Wash. , ... IT stimulus and the American Recovery and Reinvestment Act ... comprehensive digital imaging and data management integration project with ... paying dividends for MINW patients even after the completion ...
Cached Medicine News:Health News:Akron Institute of Herzing University Launches Its First Bachelor's Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT 2Health News:Akron Institute of Herzing University Launches Its First Bachelor's Degree Programs to Prepare Students for Even Greater Success in Business, Health Care and IT 3Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 2Health News:People with anxiety disorder less able to regulate response to negative emotions, study shows 3Health News:Multi-Award Winning Author Tina Turbin Interviews Special Guest Dr. Peter H.R. Green, M.D. On The Thrive in Balance Radio Show 2Health News:Physical Changes in Brain Linked to Altered Spirituality 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 3
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: